» Articles » PMID: 15842359

Shiga Toxin Enhances Functional Tissue Factor on Human Glomerular Endothelial Cells: Implications for the Pathophysiology of Hemolytic Uremic Syndrome

Overview
Publisher Elsevier
Specialty Hematology
Date 2005 Apr 22
PMID 15842359
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The pathogenesis of Shiga toxin (Stx)-mediated childhood hemolytic uremic syndrome (HUS) is not fully delineated, although current evidence implicates a prothrombotic state. We hypothesized that the tissue factor (TF) pathway plays a major role in the pathophysiology of HUS.

Materials And Methods: We measured cell surface TF activity in response to tumor necrosis factor-alpha (TNF-alpha) (20 ng mL(-1), 2-144 h), Stx-1 (10(-11) mol L(-1), 4-144 h), or their combination (TNF-alpha 22 h and Stx-1 for the last 0.5-4 h of TNF-alpha incubation) on human glomerular (microvascular) endothelial cells (HGECs) and human umbilical vein (macrovascular) endothelial cells (HUVECs).

Results And Conclusions: We observed that while TNF-alpha caused an increase in cell surface TF activity on both cell types, the combination of TNF-alpha and Stx-1 differentially affected HGECs. On these cells, TF activity was increased further by 2.67 +/- 0.38-fold (n = 38, P < 0.001), consistent with our parallel observation that Stx-1 binds to HGECs but not to HUVECs. Anti-TF antibody abolished functional TF while anti-tissue factor pathway inhibitor antibody enhanced TF activity. Stx-1 alone did not induce TF activity on either cell type. Measurement of TF antigen levels and quantitative real-time polymerase chain reaction demonstrated that exposure to TNF-alpha markedly increased TF protein and TF mRNA for HGECs, but the exposure to the combination of TNF-alpha and Stx-1 did not increase further the amount of either TF protein or TF mRNA. We conclude that cytokine-activated HGECs, but not HUVECs, undergo a significant augmentation of cell surface TF activity following exposure to Stx, suggesting an important role for TF in the coagulopathy observed in HUS.

Citing Articles

Endothelial dysfunction and immunothrombosis in sepsis.

Maneta E, Aivalioti E, Tual-Chalot S, Emini Veseli B, Gatsiou A, Stamatelopoulos K Front Immunol. 2023; 14:1144229.

PMID: 37081895 PMC: 10110956. DOI: 10.3389/fimmu.2023.1144229.


Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

Freiwald T, Afzali B Adv Immunol. 2021; 152:1-81.

PMID: 34844708 PMC: 8905641. DOI: 10.1016/bs.ai.2021.09.001.


Tissue Factor-Enriched Neutrophil Extracellular Traps Promote Immunothrombosis and Disease Progression in Sepsis-Induced Lung Injury.

Zhang H, Zhou Y, Qu M, Yu Y, Chen Z, Zhu S Front Cell Infect Microbiol. 2021; 11:677902.

PMID: 34336711 PMC: 8317465. DOI: 10.3389/fcimb.2021.677902.


Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management.

Travert B, Rafat C, Mariani P, Cointe A, Dossier A, Coppo P Toxins (Basel). 2021; 13(5).

PMID: 33925836 PMC: 8145702. DOI: 10.3390/toxins13050306.


Shiga toxin remodels the intestinal epithelial transcriptional response to Enterohemorrhagic Escherichia coli.

Warr A, Kuehl C, Waldor M PLoS Pathog. 2021; 17(2):e1009290.

PMID: 33529199 PMC: 7880444. DOI: 10.1371/journal.ppat.1009290.